Share on LinkedInShare on LinkedIn

ARTICLE · 02 JANUARY 2025

Noteworthy Hatch-Waxman Decisions From 2024

Over the past twelve months, the Federal Circuit has issued a number of noteworthy decisions that will impact litigation strategy and business planning.

United StatesIntellectual Property

Originally published on 12/20/2024, updated on 12/23/2024 to reflect updates pertaining to Teva v. Amneal.

Over the past twelve months, the Federal Circuit has issued a number of noteworthy decisions that will impact litigation strategy and business planning. Several of those cases pertain particularly to cases brought under the Hatch-Waxman Act. Here, Taft provides a brief overview of a few key Hatch-Waxman decisions from 2024.

Salix v. Norwich: Polymorph Patent Claims Are Susceptible to Obviousness Challenges

About the case

In April, the Federal Circuit breathed new life into the use of obviousness challenges to claims drawn to a drug compound's solid state form.

At issue in Salix Pharmaceuticals Ltd. v. Norwich Pharmaceuticals Inc., 98 F.4th 1056 (Fed. Cir. 2024), was Norwich's proposed generic version of rifaximin, which is the active ingredient in Salix's commercial product Xifaxan®, used to treat hepatic encephalopathy (HE) and irritable

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from